SEOM-GEICO clinical guidelines on endometrial cancer (2025)
Clinical and Translational Oncology · 2025
DOI: 10.1007/s12094-025-04046-1 ↗Kurz gefasst
Leitlinie in der Zeitschrift Clinical and Translational Oncology, 2025. Verfasst von Sara Pérez Ramírez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. sperezramirez85@gmail.com. Hauptthemen laut MEDLINE: Endometrial Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Endometrial cancer (EC) is the most common gynecological malignancy in developed countries. Although most cases are diagnosed at an early stage, prognosis in case of relapse or metastasis remains poor. Molecular characterization of EC is highly recommended as it allows more accurate risk stratification and may modify treatment recommendations. The updated FIGO 2023 staging of EC highlights the importance of traditional clinicopathological factors, while underlining the need for molecular classification to predict outcomes. In early-stage EC, standard treatment consists of total hysterectomy and bilateral salpingo-oophorectomy. Lymph node evaluation remains controversial, as the benefits of systematic lymphadenectomy are unclear. Adjuvant treatment, consisting of radiotherapy, brachytherapy, and chemotherapy, should be chosen according to risk category. In women with advanced or recurrent EC, the combination of carboplatin and paclitaxel has long been standard treatment. However, therapeutic options have changed recently due to advances in immunotherapy. The aim of this guideline is to summarize the current evidence for the diagnosis, treatment, and follow-up of EC, and to provide evidence-based recommendations for clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. sperezramirez85@gmail.com.
- Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA, Valencia, Spain.
- Department of Medical Oncology, Catalan Institute of Oncology Girona, IDIBGI-CERCA, Girona, Spain.
- Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
- Department of Medical Oncology, Hospital Universitario Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
- Department of Medical Oncology, Cancer Center Clínica Universidad de Navarra (CCUN), Madrid, Spain.
Zitieren
APA
Ramírez, S. P., Fidalgo, A. P., Ginesta, M. P. B., De Juan Ferré, A., Madrid, L. F., Martínez, A. G., Montosa, F. G., Madariaga, A., Gómez, T. M., & Gil-Martin, M. (2025). SEOM-GEICO clinical guidelines on endometrial cancer (2025). Clinical and Translational Oncology. https://doi.org/10.1007/s12094-025-04046-1
Vancouver
Ramírez SP, Fidalgo AP, Ginesta MPB, De Juan Ferré A, Madrid LF, Martínez AG, et al. SEOM-GEICO clinical guidelines on endometrial cancer (2025). Clinical and Translational Oncology. 2025. doi:10.1007/s12094-025-04046-1
BibTeX
@article{Ramrez2025,
author = {Ramírez, Sara Pérez and Fidalgo, Alejandro Pérez and Ginesta, María Pilar Barretina and De Juan Ferré, Ana and Madrid, Lorena Fariñas and Martínez, Alejandro Gallego and Montosa, Fernando Gálvez and Madariaga, Ainhoa and Gómez, Teresa Martin and Gil-Martin, Marta},
title = {SEOM-GEICO clinical guidelines on endometrial cancer (2025)},
journal = {Clinical and Translational Oncology},
year = {2025},
doi = {10.1007/s12094-025-04046-1}
}
EUVIMED